1-(1-butyl-2-phenyl-1H-imidazol-5-yl)-N-(4-methylbenzyl)-N-(1-naphthylmethyl)methanamine | 439559-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(1-butyl-2-phenyl-1H-imidazol-5-yl)-N-(4-methylbenzyl)-N-(1-naphthylmethyl)methanamine
• 英文别名: N-[(3-butyl-2-phenylimidazol-4-yl)methyl]-1-(4-methylphenyl)-N-(naphthalen-1-ylmethyl)methanamine
• CAS: 439559-87-2
• 化学式: C₃₃H₃₅N₃
• 分子量: 473.661
• InChiKey: PEXABRZTFHJJEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS
  申请人：NEUROGEN CORPORATION

  公开号：EP1490044A1

  公开（公告）日：2004-12-29
• EP1490044A4
  申请人：——

  公开号：EP1490044A4

  公开（公告）日：2008-04-16
• [EN] COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS<br/>[FR] THERAPIE COMBINATOIRE POUR LE TRAITEMENT DE MALADIES FAISANT INTERVENIR DES COMPOSANTS INFLAMMATOIRES
  申请人：NEUROGEN CORP

  公开号：WO2003084524A1

  公开（公告）日：2003-10-16

  Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio-and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.